StockNews.AI
SEER
StockNews.AI
117 days

Seer to Report First Quarter 2025 Financial Results on May 13, 2025

1. Seer will report Q1 2025 financial results on May 13. 2. Management will host a webcast at 1:30 PM PT. 3. Seer specializes in proteomics with its Proteograph™ Product Suite. 4. Proteograph enables deep proteomic analysis using engineered nanoparticles. 5. The product is solely for research, not for diagnostics.

3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results could provide positive momentum based on previous quarters. Historically, financial reports have influenced stock values significantly, especially if results are above expectations.

How important is it?

The scheduled earnings call is critical for investors monitoring growth and revenue. A solid report could affirm SEER's growth trajectory and attract further investment.

Why Short Term?

The upcoming financial results will have an immediate impact. Past earnings announcements have shown quick responses in stock movement.

Related Companies

ILMNTSLA
April 24, 2025 16:05 ET  | Source: Seer, Inc. REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio. Media Contact:Patrick Schmidt pr@seer.bio Investor Contact:Carrie Mendivilinvestor@seer.bio

Related News